Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648639 | 0.97 | AGTR1 (0.40) | AGTR1AGTR2LTB4R2LTA4HADORA3 | |
| SCHEMBL653603 | 0.97 | AGTR1 (0.40) | AGTR1AGTR2LTB4R2LTA4H | |
| SCHEMBL648516 | 0.97 | LTB4R2 (0.40) | AGTR1AGTR2LTB4R2LTA4HADORA3 | |
| SCHEMBL648502 | 0.96 | LTA4H (0.42) | AGTR1AGTR2LTB4R2LTA4HCRHR1 | |
| SCHEMBL652625 | 0.95 | LTB4R2 (0.41) | AGTR1AGTR2LTB4R2ADORA3ADORA2B | |
| SCHEMBL648589 | 0.93 | LTB4R2 (0.38) | AGTR1AGTR2LTB4R2LTA4HADORA3 | |
| SCHEMBL650060 | 0.93 | LTB4R2 (0.38) | AGTR1AGTR2LTB4R2LTA4HADORA3 | |
| SCHEMBL651348 | 0.91 | LTB4R2 (0.39) | AGTR1AGTR2LTB4R2ADORA3ADORA2B | |
| SCHEMBL651282 | 0.91 | LTB4R2 (0.39) | AGTR1AGTR2LTB4R2ADORA3ADORA2B | |
| SCHEMBL650386 | 0.91 | LTB4R2 (0.39) | AGTR1AGTR2LTB4R2ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |